Key result
Statins lack clinical benefit for dementia, while preclinical data support cyclodextrins for neuroprotection.
Why the study?
Do statins and cyclodextrins provide neuroprotective effects in the context of dementia and cognitive impairment?
Do statins and cyclodextrins provide neuroprotective effects in the context of dementia and cognitive impairment?
Answers are grounded in this paper and cite their sources.
Cyclodextrins may offer a novel therapeutic avenue for dementia treatment based on animal models, warranting future clinical trials.
SUMMARY Dementia is a progressive and irreversible deterioration in cognition that has a significant impact on the person’s activities of daily living and quality of life. Currently, there is no curative treatment for dementia, and the treatments used in clinical practice have limited therapeutic reach. We begin this descriptive review with a discussion of apolipoprotein E4 (apoE4) and its role in the pathogenesis of dementia. We consider the molecular involvement of statins and why they are no longer clinically indicated in mild cognitive impairment or mild to moderate dementia. We then explore the evidence regarding the effects of statins and cyclodextrins on apoE4, presenting evidence in support of and against their neuroprotective effects in cognitive impairment. Although the studies on cyclodextrins have all been on animals, they provide a strong background for a potential research hypothesis for future clinical trials in the treatment of dementia.
No takes yet. Share an insight, caveat, or question.
Jamali et al. (2025) conducted a review in Dementia. Statins and cyclodextrins was evaluated. Statins are no longer clinically indicated for dementia, while cyclodextrins show potential neuroprotective effects in animal models, providing a hypothesis for future clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: